Table 1.

Some characteristics of viral neuraminidase inhibitors

	Zanamivir (Relenza)	Oseltamivir (Tamiflu)	Laninamivir (R-125489)	Peramivir (Rapiacta)	TCN-032
Licensing	UK, USA	UK, USA	Japan	Japan, South Korea	Prospective
Delivery	Inhalation	Oral administration	Inhalation	Intravenous administration	Intravenous administration
Other features	Powder inhalation may be unsuitable in severe influenza	Possible mutation-induced resistance	Comparable clinical efficacy to oseltamivir and zanamivir against H1N1 pandemic and seasonal H3N2, as well as influenza B	Emergency use authorization (US) for treatment of pandemic 2009 H1N1 INFV	Does not affect M2 ion channel activity in the virion and interferes with budding Safe and relatively efficient in Phase I clinical trial

Abbreviation: INFV, influenza.